Mutations in the apolipoprotein (apo) B-100 receptor-binding region: Detection of apo B-100 (Arg3500→Trp) associated with two new haplotypes and evidence that apo B-100 (Glu3405→Gln) diminishes receptor-mediated uptake of LDL

Clinical Chemistry

Volumn 45, Issue 7, 1999, Pages 1026-1038

  Fisher, Eva ^a   Scharnagl, Hubert ^b   Hoffmann, Michael M ^b   Kusterer, Klaus ^a   Wittmann, Daniela ^a   Wieland, Heinrich ^b   Gross, Werner ^a   März, Winfried ^b  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B100; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MUTANT PROTEIN; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CHILD; DNA DETERMINATION; FEMALE; GEL ELECTROPHORESIS; GENE MUTATION; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; APOLIPOPROTEIN B-100; APOLIPOPROTEINS B; CHILD; CHILD, PRESCHOOL; CHOLESTEROL, LDL; ELECTROPHORESIS; FEMALE; HAPLOTYPES; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; MUTATION; PEDIGREE; RECEPTORS, LIPOPROTEIN;

EID: 0032802523     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34-47.
2. Kane JP, Havel RJ. Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins. In: Scriver CR, Beaudet AL, Sly WS, and Valle D, eds. The metabolic and molecular basis of inherited disease, 7th ed. New York: McGraw-Hill, 1995:1853-86.
3. Myant NB. Cholesterol metabolism, LDL, and the LDL receptor. San Diego: Academic Press, 1990:465pp.
4. Knott TJ, Pease RJ, Powell LM, Wallis SC, Rall SC, Innerarity TL, et al. Complete protein sequence and identification of structural domains of human apolipoprotein B. Nature 1986;323:734-8.
5. Yang CH, Chen SH, Gianturco SH, Bradley WA, Sparrow JT, Tanimura M, et al. Sequence, structure, receptor-binding domains and internal repeats of human apolipoprotein B-100. Nature 1986;323:738-42.
6. Pease RJ, Milne RW, Jessup WK, Law A, Provost P, Fruchart J-C, et al. Use of bacterial expression cloning to localize the epitopes for a series of monoclonal antibodies against apolipoprotein B 100. J Biol Chem 1990;265:553-68.
7. Law A, Scott J. A cross-species comparison of the apolipoprotein B domain that binds to the LDL receptor. J Lipid Res 1990;31:1109-20.
8. Innerarity TL, Weisgraber KH, Arnold KS, Mahley RW, Krauss RM, Vega GL, Grundy SM. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci U S A 1987;84:6919-23.
9. Soria LF, Ludwig EH, Clarke HRG, Vega GL, Grundy SM, McCarthy BJ. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B100. Proc Natl Acad Scl U S A 1989;86:587-91.
10. Dunning AM, Houlston R, Frostegard J, Revill J, Nilsson J, Hamsten A, et al. Genetic evidence that the putative receptor binding domain of apolipoprotein B (residues 3130 to 3630) is not the only region of the protein involved in the interaction with the low density lipoprotein receptor. Biochim Biophys Acta 1991;1096:231-7.
11. Gaffney D, Reid JM, Cameron LM, Vass K, Caslake MJ, Shepherd J, Packard CJ. Independent mutations at codon 3500 of the apolipoprotein B gene are associated with hyperlipidemia. Arterioscler Thromb 1995;15:1025-9.
12. Pullinger CR, Hennessy LK, Chatterton JE, Liu W, Love JA, Mendel CM, et al. Familial ligand-defective apolipoprotein B: identification of a new mutation that decreases LDL receptor binding affinity. J Clin Investig 1995;95:1225-34.
13. Ilmonen M, Ebeling T, Viikari J, Ojala J-P, Tikkanen MJ. Screening of the 3′ two-thirds of the coding area of the apo B gene in Finnish hypercholesterolemic patients. Report of six new genetic variants. Atherosclerosis 1997;128:191-9.
14. Ludwig EH, Hopkins PN, Allen A, Wu LL, Williams RR, Anderson JL, et al. Association of genetic variations in apolipoprotein B with hypercholesterolemia, coronary artery disease, and receptor binding of low density lipoproteins. J Lipid Res 1997;38:1361-73.
15. 3500→tryptophan mutation associated with a unique haplotype. Clin Chem 1997;43:916-23.
16. Gaffney D, Hoffs MS, Cameron IM, Stewart G, O'Reilly DSJ, Packard CJ. Influence of polymorphism Q3405E and mutation A3371V in the apolipoprotein B gene on LDL receptor binding. Atherosclerosis 1998;137:167-74.
17. Wenham PR, Henderson BG, Penney MD, Ashby JP, Rao PWH, Walker SW. Familial ligand-defective apolipoprotein B-100: detection, biochemical features and haplotype analysis of the R3531C mutation in the UK. Atherosclerosis 1997;129:185-92.
18. 3531→Cys mutations in French population. Hum Mutat 1997;10:160-3.
19. 3500→Trp mutation in hyperlipidemic Chinese. Clin Chem 1998;44:1659-65.
20. Innerarity TL, Mahley RW, Weisgraber KH, Bersot TP, Krauss RM, Vega GL, et al. Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia [Review]. J Lipid Res 1998;31:1337-49.
21. Tybjaerg-Hansen A, Gallagher J, Vincent J, Houlston R, Talmud P, Dunning AM, et al. Familial defective apolipoprotein B-100: detection in the United Kingdom and Scandinavia, and clinical characteristics of ten cases. Atherosclerosis 1990;80:235-42.
22. Rauh G, Keller C, Schuster H, Wolfram G, Zöllner N. Familial defective apolipoprotein B-100: a common cause of primary hypercholesterolemia [Review]. Clin Investig 1992;70:77-84.
23. Gelsel J, Schleifenbaum T, Weibhaar B, Oette K. Rapid diagnosis of familial defective apolipoprotein B-100. Eur J Clin Chem 1991;29:395-9.
24. Hansen PS, Rüdiger N, Tybjaerg-Hansen A, Faergeman O, Gregersen N. Detection of the apoB-3500 mutation (glutamine for arginine) by gene amplification and cleavage with Mspl. J Lipid Res 1991;32:1229-33.
25. 3500→Gln) allele specific polymerase chain reaction: large-scale screening of pooled blood samples. J Lipid Res 1992;33:1563-7.
26. Schuster H, Rauh G, Müller S, Keller C, Wolfram G, Zöllner N. Allele-specific and asymmetric polymerase chain reaction amplification in combination: a one step polymerase chain reaction protocol for rapid diagnosis of familial defective apolipoprotein B-100. Anal Biochem 1992;204:22-5.
27. Rust S, Funke H, Assmann G. Mutagenically separated PCR (MS-PCR): a highly specific one step procedure for easy mutation detection. Nucleic Acids Res 1993;21:3623-9.
28. Mamotte CDS, van Bockxmeer FM. A robust strategy for screening and confirmation of familial defective apolipoprotein B-100. Clin Chem 1993;39:118-21.
29. Lehmann R, Koch M, Pfohl M, Voelter W, Häring H-U, Liebich HM. Screening and identification of familial defective apolipoprotein B-100 in clinical samples by capillary gel electrophoresis. J Chromatogr A 1996;744:187-94.
30. 3500 to Gln mutation using a minigel format. Biotechniques 1997;22:446-7.
31. 2 precipitation and a quantitative lipoprotein electrophoresis assay. Clin Chim Acta 1986;160:1-18.
32. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
33. März W, Ruzicka V, Fisher E, Russ AP, Schneider W, Gross W. Typing of the 3′ hypervariable region of the apolipoprotein B gene: approaches, pitfalls, and applications. Electrophoresis 1993;14:169-73.
34. Boerwinkle E, Lee SS, Butler R, Schumaker VN, Chan L. Rapid typing of apolipoprotein B DNA polymorphisms by DNA amplification. Association between Ag epitopes of human apolipoprotein B-100, a signal peptide insertion/deletion polymorphism, and a 3′ flanking DNA variable number of tandem repeats polymorphism of the apolipoprotein B gene. Atherosclerosis 1990;81:225-32.
35. Talmud PJ, Tamplin OJ, Heath K, Gaffney D, Day INM, Humphries SE. Rapid testing for three mutations causing familial defective apolipoprotein B100 in 562 patients with familial hypercholesterolaemia [Letter]. Atherosclerosis 1996;125:135-7.
36. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Investig 1955;34:1345-53.
37. Goldstein JL, Brown MS. Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. J Biol Chem 1974;249:5153-62.
38. Goldstein JL, Basu SK, Brown MS. Receptor-mediated endocytosis of low-density lipoprotein in cultured cells. Methods Enzymol 1983;98:241-60.
39. März W, Baumstark. MW Scharnagel H, Ruzicka V, Buxbaum S, Herwig J, et al. Accumulation of "small dense" low density lipoproteins (LDL) in a homozygous patient with familial defective apolipoprotein B-100 results from heterogeneous interaction of LDL-subfractions with the LDL-receptor. J Clin Investig 1993;92:2922-33.
40. Poland D. Recursion relation generation of probability profiles for specific sequence macromolecules with long range correlations. Biopolymers 1974;13:1859-71.
41. Gotoh O, Tagashira Y. Locations of frequently opening regions on natural DNAs and their relation to functional loci. Biopolymers 1981;20:1043-58.
42. Huang LS, de Graaf J, Breslow JL. ApoB gene. Mspl RFLP in exon 26 changes amino acid 3611 from Arg to Gln. J Lipid Res 1988;29:63-7.
43. Ludwig EH, McCarthy BJ. Haplotype analysis of the human apolipoprotein B mutation associated with familial defective apolipoprotein B100. Am J Hum Genet 1990;47:712-20.
44. Pullinger CR, Love JA, Liu W, Hennessy LK, Ghassemzadeh M, Newcomb KC, et al. The apolipoprotein B Q3405E polymorphism has no effect on its low-density-lipoprotein receptor binding affinity. Hum Genet 1996;98:678-80.
45. Gallagher JJ, Myant NB. The affinity of low-density lipoproteins and of very-low-density lipoprotein remnants for the low-density lipoprotein receptor in homozygous familial defective apolipoprotein B-100. Atherosclerosis 1995;115:263-72.
46. Funke H, Rust S, Seedorf J, Brennhausen B, Chirazi A, Motti C, Assmann G. Homozygosity for familial defective apolipoprotein B-100 (FDB) is associated with lower plasma cholesterol concentrations than homozygosity for familial hypercholesterolemia (FH). Circulation 1992;86(Suppl I):I-691.
47. Avoustin P, Mostachi H, Perret B, Cambou JP, Cambien F, de Preval C. A very conservative region of ApoB-100 in the putative binding region to the LDL receptor in the Toulouse population. Hum Genet 1992;90:460-3.
48. Ilmonen M, Heliö T, Ebeling T, Pyörälä K, Uusitupa M, Palotie A, Tikkanen MJ. Screening for mutations in the exon 26 of the apolipoprotein B gene in hypercholesterolemic Finnish families by the single-strand conformation polymorphism method. Hum Mutat 1994;4:217-23.
49. Nissen H, Hansen PS, Faergeman O, Horder M. Mutation screening of the codon 3500 region of the epolipoprotein B gene by denaturing gradient-gel electrophoresis. Clin Chem 1995;41:419-23.
50. Henderson BG, Wenham PR, Ashby JP, Blundell G. Detecting familial defective apolipoprotein B-100: three molecular scanning methods compared. Clin Chem 1997;43:1630-4.
51. Kotze MJ, Langenhoven E, Peeters AV, Theart L, Oosthuizen CJJ. Detection of two point mutations causing familial defective apolipoprotein B-100 by heteroduplex analysis. Mol Cell Probes 1994;8:513-8.
52. Ludwig EH, Blackhart BD, Pierotti VR, Caiati L, Fortier C, Knott T, et al. DNA sequence of the human apolipoprotein B gene. DNA 1987;6:363-72.
53. Assmann G, Cullen P, Schulte H. The Münster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J 1998;19(Suppl A):A2-11.
54. Miserez AR, Laager R, Chiodetti N, Keller U. High prevalence of familial defective apolipoprotein B-100 in Switzerland. J Lipid Res 1994;35:574-83.
55. Innerarity TL, Borén J. The receptor- and proteoglycan-binding sites of LDL: engineering a nonatherogenic LDL [Abstract]. 13th International Symposium on Drugs Affecting Lipid Metabolism, Florence, May 30-June 3, 1998:7.
56. Boerwinkle E, Xiong W, Fourest E, Chan L. Rapid typing of tandemly repeated hypervariable loci by the polymerase chain reaction: application to the apolipoprotein B 3′ hypervariable region. Proc Natl Acad Sci U S A 1989;86:212-6.